Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ainos, Inc. - Common Stock (NQ: AIMD )

0.7390 +0.0090 (+1.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 148,613
Open 0.7500
Bid (Size) 0.7200 (4)
Ask (Size) 0.7493 (3)
Prev. Close 0.7300
Today's Range 0.7080 - 0.7500
52wk Range 0.4000 - 3.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
Via ACCESS Newswire
Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025
Via ACCESS Newswire

Performance

YTD
+47.80%
+47.80%
1 Month
+13.69%
+13.69%
3 Month
+71.46%
+71.46%
6 Month
+13.60%
+13.60%
1 Year
-10.96%
-10.96%

More News

Read More
Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule
Via ACCESS Newswire
Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
Via ACCESSWIRE
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
Via ACCESSWIRE
Ainos Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
Via ACCESSWIRE
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
Via ACCESSWIRE
Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement
Via ACCESSWIRE
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing
Via ACCESSWIRE
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
Via ACCESSWIRE
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
Via ACCESSWIRE
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
Via ACCESSWIRE
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
Via ACCESSWIRE
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Via ACCESSWIRE
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
Via ACCESSWIRE
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
Via ACCESSWIRE
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter
Via ACCESSWIRE
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Via ACCESSWIRE
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.